论文部分内容阅读
自1967年发现乙型肝炎病毒(HBV)以来,人们对HBV感染自然史及防治的认识有了很大提高,慢性乙型肝炎(CHB)治疗模式和患者管理计划也在不断完善。研究表明,病毒载量是CHB进展为肝硬化及肝癌的独立危险因素~([1-2])。有效的抗病毒治疗可以延缓或阻止CHB的疾病进程~([3])。由于目前对进入体内的HBV仍无法根除,所以CHB的临床治疗是从不断实现短期目标(HBV DNA低于检测值下限、丙氨酸转氨酶复常、HBeAg阳性患者血清学转换)迈向实现长期目标(预防肝纤维化发展为肝硬化和肝癌)的过程,从而达到提高患者生活质量、延长患者生存时间的目标。持久的病毒抑制是
Since the discovery of Hepatitis B virus (HBV) in 1967, people’s awareness of the natural history and prevention and treatment of HBV infection has been greatly improved. The CHB treatment model and patient management plan are also constantly improving. Studies have shown that viral load is an independent risk factor for the progression of CHB to cirrhosis and hepatocellular carcinoma ([1-2]). Effective antiviral therapy can delay or prevent CHB disease process ~ ([3]). As the current entry into the body of HBV still can not eradicate, so the clinical treatment of CHB from the continuous realization of short-term goals (HBV DNA below the lower limit of detection, alanine aminotransferase, HBeAg positive seroconversion) towards long-term goal (Prevent the development of liver fibrosis and liver cirrhosis) process, so as to improve the quality of life of patients and extend the survival of patients with the goal. Long lasting viral suppression is